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Introduction.– The Complex regional pain syndrome (CRPS) presents serious
therapeutic difficulties. Two types of this syndrome are known: type I without
peripheral nerve lesion and type II with peripheral nerve lesion. Three stages are
described: stage one with vasomotor troubles and allodynia, the stage two with
hypoesthesia, then, the stage threewith decreased range of motion. Here is, a CRPS
case with neuropathic pain which was treated with somatosensory rehabilitation.
Observation.– A 64-year-old woman, was suffering from a CRPS type II in first
stage in acromioplastia post-surgical of left shoulder in October 2011. The
CRPS was diagnosed with Bruehl criteria and a scintigraphy.
The somatosensory rehabilitation was started in March 2012. The patient took
analgesic pills which did not much relieved the pain. A map of the allodynia
enabled to evaluate the intensity of neuropathic pain and identify the reached
nerve. This sensitive cartographia was effected with a monofilament 15 g. A
painful zone with a personal EVA > 3/10 was delimitated. Then, in this territory,
the intensity of allodynia was dertermined with other thinner monofilaments.
Here, the reached nerve was the superior branch of lateral skin nerve of the left
arm.
The somatosensory rehabilitation consisted in:
– a distant vibrotactile counter stimulation 8 times a day during 1 minute with
confortable stimuli in C8-D1;
– a distant viber counter stimulation realised with Vibralgic at 300 Hz, 0.9 v
during less than 1 minute;
– none stimuli on the allodynia territory.
An assisted active range of motion exercise of the left shoulder was effected.
The pain was gone, the allodynic territory had decreased to disappear one month
later. The patient did not take treatment any longer. The range of motion of
shoulder was normal.
Discussion.– The treatment of CRPS must start early with interdisciplinary
management. Many treatments have been effected no so successfully and with
sometimes severe side effects. New techniques, like mirror therapy or
somatosensory rehabilitation could be explored.
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The action of the toxin botulinum of type A (TBA) on the abnormal
hyperactivity of the piriformis muscle in the rest is a hypothesis allowing to
think that the decrease of this hyperactivity, witness of the muscle spasm, comes
along with an improvement of the painful of the patients.
Patients and method.– It is the retrospective study which allowed to include
patients with piriformis syndrome [2–4], distributed in two groups (neurological
G1, not neurological G2).
Method:
– the clinical evaluation [3,4] and the EMG detection: activities of muscular not
looseness during the muscular relaxation in the piriforme [3], allowed the
inclusion, the absence of hyperactivity excluded the patients;
– the injection of TBA during EMG was realized with location of the muscular
activities. A control EMG in 3 months was planned.
Results.– Twenty-five inclusive patients mailed: 17 injections of TBA (7 group
1, 10 group 2), 8 excluded patients.
The modification of the muscle spasm noticed in the EMG by the decrease of the
muscular hyperactivity is not correlated in a significant modification of the pain
(3/6 months later).
Discussion.– This preliminary study allows to define the electrophysiologics
criteria necessary to propose an injection of TBA in the piriformis muscle in the
contact of the hyperactive driving plate the clinicals and the electrophysiologics
results, to compare them with the previous works [1,2,5].
One prospective study is necessary by including these electrophysiologic
criteria during the injection.
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Introduction.– Mobilization of a stiff knee in NITROUS within a complex
regional pain syndrome type I of a case.
Objectives.– Nitrous oxide interest in pain management for a joint job gain.
Clinical case.– Mrs H.F., 45 years, CRPS type I in the right knee of
posttraumatic origin.
Clinical examination.– Diagnostic criteria and severity score CRPS Budapest.
At least one symptom in each group is present.
At least one sign in the four groups was found.
Total number of symptoms and signs present: 12/18.
Walk with 2 CA with stiffness in his right knee, independent with ADL in long
sick.
Support.– Day hospital with physical therapy at 3 times/week.
Intolerance TT requires dose adjustment (maximum tolerated 10 mg).
Mobilization painful; flexion 708, extension 08 after 16 weeks.
Making use of nitrous oxide for its analgesic and relaxant [2] and its safe use to
maintain the swallowing reflex [1].
After explanation of the gesture, nitrous oxide administration (maxi/5 min, flow
12 L) before mobilization followed by a gentle passive mobilization (flow 12 L,
maxi/20 min) with bending posture respecting the no pain.
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Twelve sessions were conducted.
Results.– Amnesic effect on pain may occur during mobilization.
Flexion: 958 active.
Pain: 0/10 at rest and walking.
Improving the quality of walking with a smooth and not increase walking speed
without technical assistance.
Resumption of his previous 26 months work after the diagnosis of CRPS-I.
Scintigraphy: net regression process CRPS-I detected in his right knee in 2010.
Regularization of all households hyperactive.
Discussion and conclusion.–This would be for the benefit of nitrous oxide in the
mobilization of a stiff joint including CRPS-I through a permitting algo-
functional improvement and joints that enabled our patient to return to his
previous work.
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Introduction.– Intrathecal ziconotide has shown its efficiency in chronic
resistant pain, we studied the association with baclofene in spastic pain
management.
Patients.– Seven patients, 4 female, 3 male, average age 54.3 years old [39; 75]
have been treated with continuous intrathecal infusion of baclofene, ziconotide
and morphine. Four had a failed back surgery syndrome, 1 peripherical nerve
lesion, 1 spine injury, 1 cerebral palsy. Ziconotide has been introduced after the
failure of an intrarachidian morphine + baclofene treatment.
Results.– The average decrease of pain intensity after we began the ziconotide
treatment was equal to 31 mm on visual analog pain scale, from 68 to 37 mm
efter ziconotide introduction. Ziconotide adding had no effect on spasticity
which was already efficiently managed by intrathecal baclofene. The average
follow-up was 13.3 months [2; 26 months]. Average ziconotide posologies were
3.1 mg per day [1.25; 5.7 mg per day] and 342 mg per day [43; 1800 mg per day]
for baclofene. Ziconotide had to be stopped for 3/7 (43%) because of side
effects, with a full recovery after treatment interruption. One patient kept
auditory hallucination but did not want any posology modification since he was
satisfied with the antalgic level. Most of the side effects occurred during the first
semester of our using of ziconotide due to a too fast dose increase. The
commonest side effects were: nausea, dizziness, ataxia, visual and/or auditory
hallucination. No treatment failure has been noticed for two years. Initial
treatment administration has to be as low as possible (1 mg per day in our
population) in order to obtain antalgic effect without major side effects. A slight
increase of doses (+0.3 mg per week) allows pain management without side
effects.
Conclusion.– Ziconotide in association with intrathecal baclofene is a good way
to deal with chronic pain with spasticity.
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The algodystrophy is a regional pain syndrome, characterized by complex
neurovascular abnormalities. Pregnancy appears through mechanical factors
promote dystrophy of the lower limbs. We report a case of bilateral hip
dystrophy diagnosed during postpartum.
This is a 31-year-old woman, primipara, who presented in the third quarter of
pregnancy (35 weeks gestation) mechanical bilateral groin pain with functional
impairment. She has consulted in postpartum (4 days after birth). The review
noted a limp, functional impairment with a VAS pain 70%. Standard
radiographs postpartum showed speckled locoregional demineralization hips.
MRI confirmed the diagnosis of CRPS hips. The patient took analgesic
treatment with a discharge and rest for 3 months. She has not received
bisphosphonates because she breastfeeding. Disease duration was 24 weeks.
The evolution was marked by the persistence of residual pain (VAS 20%)
without sequelae.
The analysis of our results compared to literature, allows to identify the main
characteristics of this variety of reflex sympathetic dystrophy: gradual onset in
the second or third trimester, location in the hip alone or associated with other
locations [1–3]. MRI is currently the modality of choice for the early and
differential diagnosis [1,3]. The course is generally favorable [3].
Algodystrophy during pregnancy is rare and is often misunderstood. MRI have
an important place in the diagnosis of this disease. The safety of
bisphosphonates during pregnancy and lactation remains to be demonstrated.
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Objective.– The study of the literature concerning the treatment of piriformis
muscle syndrome (PMS) to validate the role of botulinum toxin injections
performed after failure of medical management and rehabilitation. The few
reported series confirm the results significantly superior to placebo injections
and even repeated anesthetics and/or corticosteroids. The piriformis muscle
belongs to the deep part of the gluteal region where the need for radiological
identification. Our team couples the ultrasound with electromyography
detection, allowing the latter through an active lateral rotation maneuver (in
a subject supine on the healthy side) to optimize the injection site. Ultrasound,
with constant technical progress and the development of new sensors, allows
very interesting morphological evaluation of the muscle and its relationship
with the main sciatic nerve. The objective of this study was to validate the
clinical and ultrasonographic markers compared to CT and anatomical data.
Patients and methods.– Five patients supported for SMP received botulinum
toxin injections under ultrasound and CT with a minimum of 3 months between
each injection, the second injection performed because of insufficient
improvement of symptoms.
Results.– The clinical markers of projection of the piriformis muscle is defined
by a triangle whose base joins the posterior superior iliac spine and the upper
part of the inter-gluteal fold, and whose summit is next to the upper pole of the
greater trochanter. Ultrasound (abdominal convex probe tone) body muscle is
visualized on the lateral edge of the sacrum with a depth of 4.8 cm for the
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